108 related articles for article (PubMed ID: 21159836)
1. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
2. B cell depletion in systemic lupus erythematosus.
Leandro MJ; Ehrenstein MR
Clin Med (Lond); 2007; 7(1):57-9. PubMed ID: 17348577
[No Abstract] [Full Text] [Related]
3. Rituximab in immunologic glomerular diseases.
Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
[TBL] [Abstract][Full Text] [Related]
4. B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Pescovitz MD; Greenbaum CJ; Bundy B; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; Moran A; Raskin P; Rodriguez H; Schatz DA; Wherrett DK; Wilson DM; Krischer JP; Skyler JS;
Diabetes Care; 2014 Feb; 37(2):453-9. PubMed ID: 24026563
[TBL] [Abstract][Full Text] [Related]
5. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.
Colucci M; Carsetti R; Cascioli S; Casiraghi F; Perna A; Ravà L; Ruggiero B; Emma F; Vivarelli M
J Am Soc Nephrol; 2016 Jun; 27(6):1811-22. PubMed ID: 26567244
[TBL] [Abstract][Full Text] [Related]
6. An update on the biologics for the treatment of antiphospholipid syndrome.
Yun Z; Duan L; Liu X; Cai Q; Li C
Front Immunol; 2023; 14():1145145. PubMed ID: 37275894
[TBL] [Abstract][Full Text] [Related]
7. T Cell Abnormalities in X-Linked Agammaglobulinaemia: an Updated Review.
Chawla S; Jindal AK; Arora K; Tyagi R; Dhaliwal M; Rawat A
Clin Rev Allergy Immunol; 2023 Aug; 65(1):31-42. PubMed ID: 35708830
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis E Virus Infection-Immune Responses to an Underestimated Global Threat.
Kupke P; Werner JM
Cells; 2021 Sep; 10(9):. PubMed ID: 34571931
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.
Richard SA; Kampo S; Hechavarria ME; Sackey M; Buunaaim ADB; Kuugbee ED; Anabah TW
J Immunol Res; 2020; 2020():4582612. PubMed ID: 33062720
[TBL] [Abstract][Full Text] [Related]
10. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.
Nakayamada S; Tanaka Y
Inflamm Regen; 2016; 36():6. PubMed ID: 29259679
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?
Schreiber K; Nocturne G; Cornec D; Daïen CI
Clin Rev Allergy Immunol; 2017 Oct; 53(2):277-290. PubMed ID: 28560621
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.
Madanchi N; Bitzan M; Takano T
Can J Kidney Health Dis; 2017; 4():2054358117698667. PubMed ID: 28540057
[TBL] [Abstract][Full Text] [Related]
13. B lymphocytes in renal interstitial fibrosis.
Zhu F; Bai X; Chen X
J Cell Commun Signal; 2017 Sep; 11(3):213-218. PubMed ID: 28210941
[TBL] [Abstract][Full Text] [Related]
14. Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.
Dörner T; Lipsky PE
Nat Rev Rheumatol; 2016 Nov; 12(11):645-657. PubMed ID: 27733759
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
16. Rationale for B cell targeting in SLE.
Sanz I
Semin Immunopathol; 2014 May; 36(3):365-75. PubMed ID: 24763533
[TBL] [Abstract][Full Text] [Related]
17. B-cell-mediated strategies to fight chronic allograft rejection.
Dalloul A
Front Immunol; 2013 Dec; 4():444. PubMed ID: 24381571
[TBL] [Abstract][Full Text] [Related]
18. B cell-regulated immune responses in tumor models and cancer patients.
Fremd C; Schuetz F; Sohn C; Beckhove P; Domschke C
Oncoimmunology; 2013 Jul; 2(7):e25443. PubMed ID: 24073382
[TBL] [Abstract][Full Text] [Related]
19. B-cell targeted therapeutics in clinical development.
Blüml S; McKeever K; Ettinger R; Smolen J; Herbst R
Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S4. PubMed ID: 23566679
[TBL] [Abstract][Full Text] [Related]
20. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile.
DeFuria J; Belkina AC; Jagannathan-Bogdan M; Snyder-Cappione J; Carr JD; Nersesova YR; Markham D; Strissel KJ; Watkins AA; Zhu M; Allen J; Bouchard J; Toraldo G; Jasuja R; Obin MS; McDonnell ME; Apovian C; Denis GV; Nikolajczyk BS
Proc Natl Acad Sci U S A; 2013 Mar; 110(13):5133-8. PubMed ID: 23479618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
